CXCR4 and diffuse large B-cell lymphoma: We determined CXCR4 expression to be significantly associated with outcome in a cohort of 233 R-CHOP-treated DLBCL patients, demonstrating a decreased 5-year OS for patients with high CXCR4 expression (Figure 1).